
ETF¹²⁸®/ETF^{Mx} Clinical White Paper/FAQ

The 128 Hz tuning fork has long been used by a variety of medical professionals for the assessment of vibratory sensation. Although the tuning fork has proven its utility over time, little has been done to improve its design since being introduced into clinical medicine in the 19th century. In light of this history, O'Brien Medical envisioned a 21st century version of this venerable instrument taking advantage of advances in modern electrical design techniques. The **ETF¹²⁸** is the first medical-grade 128Hz electronic tuning fork. The **ETF^{Mx}** extends the capabilities of the base unit by providing two additional frequencies, 64 and 256 Hz.


The **ETF** recreates the amplitude, frequency and decay rate of the traditional tuning fork. This new electronic configuration provides a standardized output between users and patients. Additionally, the integrated timer now allows users to perform accurate timed vibration tests which have been shown to be a reliable method of assessing large fiber nerve function (1,2). Four additional output modes have been included for clinicians and researchers to use as desired.

1. Output Modes

- **64, 128, 256 Hz Descending:** This mode creates the same output as the traditional tuning fork. Vibrational output amplitude starts out high and tapers to zero over a 25 second period. In clinical use, patients will tell providers when they can no longer feel the vibrations. This point is known as vibration perception threshold (VPT) disappearance.
- **64, 128, 256 Hz Ascending:** Vibrational output amplitude in this mode is the reverse of the traditional tuning fork. Amplitude starts at zero and progresses to its highest point over a 25 second period. The point at which patients start to feel the vibrations is known as VPT appearance. It is possible that some patients may find it easier to identify when this point appears as opposed to VPT disappearance (3).
- **64, 128, 256 Hz Constant:** This mode provides constant vibrational output amplitude set to the equivalent of the 25v level in a traditional biothesiometer. This allows users to quickly assess patients for the presence or absence of neuropathy using this established reference standard (4). It should be noted that 3 seconds in the Descending and Ascending Modes is also equivalent the 25v biothesiometer output. Additionally, some users may prefer this mode for testing by the On-Off method (3).
- **128 Hz Fx Test:** This mode provides a constant maximum output of vibrations at 128Hz for as long as the user holds down the Run button. Users hold the contact tip on suspected fracture or stress fracture sites and see if a pain response is elicited. Traditional tuning forks have been used for this purpose to screen for potential fractures for many decades (5,6).
- **128 Hz Averaging:** This mode combines the descending and ascending modes into a two-step test. The user interface will take clinicians and patients through descending and ascending tests. The resulting "Vibroception Average" is then displayed. Some researchers suggest this averaging technique may be more representative of a patient's vibratory sensation than VPT appearance or disappearance alone. (7)

1. **Where does the Hallux 128 Hz Timed Vibration Test (TVT) Score come from? What does it mean?** The cutoff values were derived initially from a study done utilizing a proof-of-concept prototype ETF. This study postulated cutoff values in seconds through correlation with 10 gm monofilament and biothesiometer testing (8). The score is in approximate agreement with another researcher's suggestions for diabetic ulcer risk assessment using the TVT (9). A study with the commercial version of the ETF was then published assessing the combined utility of the ETF and Semmes-Weinstein monofilament in the prediction of diabetic foot ulcers. This study confirmed that patients with TVT values of less than 4 seconds on the ETF scale were most at risk for future ulceration. Interestingly, combining both tests had the best predictive value for ulceration (10). The current scoring system is designed to provide clinicians with **actionable data** for stratifying risks associated with diabetic peripheral neuropathy. The scale has been refined to reduce testing time and provide clear guidance on foot risk. Those patients identified with higher risk (<4 seconds) should promptly start aggressive preventive strategies aimed at reducing complications.

Hallux 128 Hz TVT



2. **What type of nerve function is assessed by the ETF?** Vibration testing has traditionally been used for assessment of large fiber nerve function. Large fiber nerves are known to register vibration, light touch, and position sense. Damage to these nerves results in a general sense of numbness which can potentially lead to diabetic foot complications. The vibrations created by the **ETF** primarily stimulate Pacinian corpuscles which are most sensitive in the 60-400 Hz range. Periosteum, known to be rich in these receptors, makes bony prominences excellent sites for vibration testing. Meissner's corpuscles (20-50 Hz) and Merkel disk receptors (5-15 Hz) found mostly in the dermis are also stimulated to a lesser degree. Action potentials generated by these three mechanoreceptors are transmitted to the posterior column of the spinal cord through large and medium myelinated nerve afferents and then to the brain where they are perceived.
3. **What anatomic locations can be tested?** As with the traditional tuning fork, any body site can be tested. The first studies with the **ETF** have focused on vibration testing at the dorsal aspect of the hallux. This is the most commonly noted site for vibration testing in diabetic patients. Some researchers advocate testing the plantar aspect of the distal hallux (i.e. the pulp of the hallux). It is unclear if there is a

diagnostically significant disparity between the two sites making this a potential area of future research.

It should be noted that the current scoring system is derived from studies on the hallux. Other locations which may be more or less sensitive than the hallux will require further research to delineate site-specific scoring. For example, one study with the *ETF* revealed relative sensory sparing at the 5th metatarsal head compared to the hallux in diabetic patients with neuropathy (11).

4. Does age affect vibratory sensation? Does this affect the TVT Score?

Yes, there is an age-related decline in vibratory sensation. One study found that many otherwise healthy participants over 70 years of age had lost varying degrees of vibration sense (12). Although this “senescent neuropathy” may be common, it still represents a deficit. Given the importance of proprioception, this could make the *ETF* a particularly useful proxy test for assessing balance sense in geriatric patients.

5. How do I hold the unit against the patient’s skin?

The *ETF* should be held perpendicularly to the skin during testing. Any off axis positioning may result in less than optimal vibration transmission.

6. How do I change the batteries?

A small flat-head screw driver or finger nail can be used to detach the battery door on the back side of the unit. Three “AAA” batteries are required for operation. Replace batteries when the “Replace Battery” message displays. In order to provide a standardized vibratory output, the unit will stop functioning below a set power level. When the unit reaches this threshold, the batteries must be replaced to resume testing. The unit is expected to perform for 6-8 weeks with moderate use*.

7. How do I clean the unit? The unit may be wiped clean with isopropyl alcohol or with soapy water and a damp towel. It is recommended that the contact tip be wiped clean with alcohol before and after each patient use.

*Based on 280 patient tests in TVT 128Hz Descending mode (two individual test sites/patient) over the course of 8 weeks.

References

1. Botez SA, Liu G, Logigian E, Herrmann DN. Is the bedside timed vibration test reliable? *Muscle Nerve* 2009; 39: 221-223.
2. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. *Diabetes Care* 2001; 24: 250-256.
3. Duke J, McEvoy M, Sibbritt D, Guest M, Smith W, Attia J. Vibrotactile threshold measurement for detecting peripheral neuropathy: defining variability and a normal range for clinical and research use. *Diabetologia*. 2007; 50: 2305-12.
4. Miranda-Palma B, Sosenko JM, Bowker JH, Mizel MS, Boulton AJ. A comparison of the monofilament with other testing modalities for foot ulcer susceptibility. *Diabetes Res Clin Pract*. 2005 Oct;70(1):8-12.
5. Fatima ST, Jeilani A, Mazhar-ud-Duha, et al. Validation of tuning fork test in stress fractures and its comparison with radionuclide bone scan. *J Ayub Med Coll Abbottabad*. 2012 Jul-Dec;24(3-4):180-2.

6. Dissmann PD, Han KH. The tuning fork test--a useful tool for improving specificity in "Ottawa positive" patients after ankle inversion injury. *Emerg Med J.* 2006 Oct;23(10):788-90.
7. Martin CL, Waberski BH, Pop-Busui R, Cleary PA, Catton S, Albers JW, Feldman EL, Herman WH. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. *Diabetes Care* 2010; 33: 2635-41.
8. O'Brien T, Karem J. An Initial Evaluation of a Proof-of-Concept 128-Hz Electronic Tuning Fork in the Detection of Peripheral Neuropathy. *Journal of the American Podiatric Medical Association* 2014; 104: 134-140.
9. Oyer, D. et al. Quantitative assessment of diabetic peripheral neuropathy with the clanging tuning fork test. *Endocrine Practice* 2007; 13:5-10.
10. O'Brien, T, Karem, J. Combined Utility of the Semmes-Weinstein Monofilament and Timed Vibration Test in the Prediction of Diabetic Foot Ulcers. *Journal of the American Podiatric Medical Association* Vol. 112, No.1, 2022.
11. O'Brien T, Karem J. Relative sensory sparing in the diabetic foot implied through vibration testing *Diabetic Foot & Ankle* 2013, 4: 21278 - <http://dx.doi.org/10.3402/dfa.v4i0.21278>
12. Thomson FJ, Masson EA, Boulton AJ. Quantitative Vibration Perception Testing in Elderly People: An Assessment of Variability. *Age and Ageing* 1992; 21: 171-174.

© 2022/23 O'Brien Medical, LLC All rights reserved. No one is permitted to reproduce or duplicate, in any form, this document or any part thereof without permission from O'Brien Medical. O'Brien Medical assumes no responsibility for any injury to anyone, or for any illegal or improper use of the product, that may result from failure to properly use the product in accordance with the instructions, cautions, or statement of intended use published in the instruction manual.

ETF¹²⁸ ® and **ETF^{Mx}** ™ are trademarks of O'Brien Medical, LLC.

Questions or Comments about O'Brien Medical products? www.obimed.com

Manufactured for O'Brien Medical, LLC 16 Winterhaven Drive Orono, Maine USA 04473

U.S. Patents 8,684,945 and 8,795,190.

